New prospects for drug development: The hedgehog pathway revealed. Focus on hematologic malignancies

Future Oncology

Volumn 9, Issue 5, 2013, Pages 681-697

  Pimentel, Agustin ^a   Velez, Michel ^a   Barahona, Luz J ^a   Swords, Ronan ^a   Lekakis, Lazaros ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Gli; hedgehog; leukemia; lymphoma; myeloma; smoothened

Indexed keywords

ABC TRANSPORTER; ARSENIC TRIOXIDE; BMS 833923; CETUXIMAB; CISPLATIN; CYTARABINE; HEPARIN; PF 04449913; PONATINIB; RETINOIC ACID; SARIDEGIB; SHORT HAIRPIN RNA; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER STEM CELL; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; EXCISION REPAIR; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMORRHAGIC GASTRITIS; HUMAN; HYPOXIA; LARGE CELL LYMPHOMA; LIGAND BINDING; MANTLE CELL LYMPHOMA; MEDULLOBLASTOMA; METASTASIS POTENTIAL; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UBIQUITINATION; WNT SIGNALING PATHWAY;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HEDGEHOG PROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION;

EID: 84877598167     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.10     Document Type: Review

References (162)

1. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 287(5785), 795-801 (1980).
2. Basler K, Struhl G. Compartment boundaries and the control of Drosophila limb pattern by hedgehog protein. Nature 368(6468), 208-214 (1994).
3. Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking sonic hedgehog gene function. Nature 383(6599), 407-413 (1996).
4. Ingham PW, Taylor AM, Nakano Y. Role of the Drosophila patched gene in positional signalling. Nature 353(6340), 184-187 (1991).
5. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14(1), 78-81 (1996).
6. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272(5268), 1668-1671 (1996).
7. Pastorino L, Ghiorzo P, Nasti S, et al. Identification of a SUFU germline mutation in a family with gorlin syndrome. Am. J. Med. Genet. A 149A(7), 1539-1543 (2009).
8. Cohen MM Jr. Hedgehog signaling update. Am. J. Med. Genet. A 152A(8), 1875-1914 (2010).
9. Chen X, Tukachinsky H, Huang CH, et al. Processing and turnover of the hedgehog protein in the endoplasmic reticulum. J. Cell Biol. 192(5), 825-838 (2011).
10. Callejo A, Bilioni A, Mollica E, et al. Dispatched mediates hedgehog basolateral release to form the long-range morphogenetic gradient in the Drosophila wing disk epithelium. Proc. Natl Acad. Sci. USA 108(31), 12591-12598 (2011).
11. Kim J, Kato M, Beachy PA. Gli2 trafficking links hedgehog-dependent activation of smoothened in the primary cilium to transcriptional activation in the nucleus. Proc. Natl Acad. Sci. USA 106(51), 21666-21671 (2009).
12. Yang L, Xie G, Fan Q, Xie J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29(4), 469-481 (2010).
13. Kinzler KW, Vogelstein B. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol. Cell. Biol. 10(2), 634-642 (1990).
14. Winklmayr M, Schmid C, Laner-Plamberger S, et al. Non-consensus GLI binding sites in hedgehog target gene regulation. BMC Mol. Biol. 11, 2 (2010).
15. Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 9(7), 873-886 (2009).
16. Hui CC, Angers S. Gli proteins in development and disease. Ann. Rev. Cell Dev. Biol. 27, 513-537 (2011).
17. Bhatia N, Thiyagarajan S, Elcheva I, et al. Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J. Biol. Chem. 281(28), 19320-19326 (2006).
18. Gulino A, Di Marcotullio L, Canettieri G, De Smaele E, Screpanti I. Hedgehog/Gli control by ubiquitination/acetylation interplay. Vitam. Horm. 88, 211-227 (2012).
19. Fernandez-Zapico ME. Primers on molecular pathways Gli: more than just hedgehog? Pancreatology 8(3), 227-229 (2008).
20. Milenkovic L, Scott MP, Rohatgi R. Lateral transport of smoothened from the plasma membrane to the membrane of the cilium. J. Cell Biol. 187(3), 365-374 (2009).
21. Fereshteh M, Ito T, Kovacs JJ, et al. b arrestin2 mediates the initiation and progression of myeloid leukemia. Proc. Natl Acad. Sci. USA 109(31), 12532-12537 (2012).
22. Kovacs JJ, Whalen EJ, Liu R, et al. Beta-arrestin-mediated localization of smoothened to the primary cilium. Science 320(5884), 1777-1781 (2008).
23. Yue S, Chen Y, Cheng SY. Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway. Oncogene 28(4), 492-499 (2009).
24. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 119(10), 2196-2204 (2012).
25. Johnson RW, Nguyen MP, Padalecki SS, et al. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling. Cancer Res. 71(3), 822-831 (2011).
26. Fan Q, He M, Sheng T, et al. Requirement of TGF beta signaling for smo-mediated carcinogenesis. J. Biol. Chem. 285(47), 36570-36576 (2010).
27. Dennler S, Andre J, Verrecchia F, Mauviel A. Cloning of the human GLI2 promoter: transcriptional activation by transforming growth factor-beta via SMAD3/beta-catenin cooperation. J. Biol. Chem. 284(46), 31523-31531 (2009).
28. Dennler S, Andre J, Alexaki I, et al. Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67(14), 6981-6986 (2007).
29. Nakashima H, Nakamura M, Yamaguchi H, et al. Nuclear factor-kappab contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 66(14), 7041-7049 (2006).
30. Koga K, Nakamura M, Nakashima H, et al. Novel link between estrogen receptor alpha and hedgehog pathway in breast cancer. Anticancer Res. 28(2A), 731-740 (2008).
31. Rajurkar M, De Jesus-Monge WE, Driscoll DR, et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc. Natl Acad. Sci. USA 109(17), E1038-E1047 (2012).
32. Kasai K, Inaguma S, Yoneyama A, Yoshikawa K, Ikeda H. SCL/TAL1 interrupting locus derepresses GLI1 from the negative control of suppressor-of-fused in pancreatic cancer cell. Cancer Res. 68(19), 7723-7729 (2008).
33. Madhala-Levy D, Williams VC, Hughes SM, Reshef R, Halevy O. Cooperation between Shh and IGF I in promoting myogenic proliferation and differentiation via the MAPK/ERK and PI3K/Akt pathways requires Smo activity. J. Cell. Physiol. 227(4), 1455-1464 (2012).
34. Beauchamp E, Bulut G, Abaan O, et al. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 284(14), 9074-9082 (2009).
35. Wang Y, Ding Q, Yen CJ, et al. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer cell 21(3), 374-387 (2012).
36. Noubissi FK, Goswami S, Sanek NA, et al. Wnt signaling stimulates transcriptional outcome of the hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 69(22), 8572-8578 (2009).
37. Uhmann A, Niemann H, Lammering B, et al. Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation. Mol. Cancer Ther. 10(11), 2179-2188 (2011).
38. Stecca B, Ruiz I Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J. 28(6), 663-676 (2009).
39. Kudo K, Gavin E, Das S, Amable L, Shevde LA, Reed E. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 31(44), 4718-4724 (2012).
40. Steg AD, Bevis KS, Katre AA, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 18(3), 869-881 (2012).
41. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26(38), 5674-5679 (2007).
42. Wong SY, Reiter JF. The primary cilium at the crossroads of mammalian hedgehog signaling. Curr. Top. Dev. Biol. 85, 225-260 (2008).
43. Litingtung Y, Lei L, Westphal H, Chiang C. Sonic hedgehog is essential to foregut development. Nat. Genet. 20(1), 58-61 (1998).
44. Kolterud A, Grosse AS, Zacharias WJ, et al. Paracrine hedgehog signaling in stomach and intestine: new roles for hedgehog in gastrointestinal patterning. Gastroenterology 137(2), 618-628 (2009).
45. Merchant JL. Hedgehog signalling in gut development, physiology and cancer. J. Physiol. 590(Pt 3), 421-432 (2012).
46. Cridland SO, Keys JR, Papathanasiou P, Perkins AC. Indian hedgehog supports definitive erythropoiesis. Blood Cells Mol. Dis. 43(2), 149-155 (2009).
47. Dyer MA, Farrington SM, Mohn D, Munday JR, Baron MH. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development 128(10), 1717-1730 (2001).
48. Makela JA, Saario V, Bourguiba-Hachemi S, et al. Hedgehog signalling promotes germ cell survival in the rat testis. Reproduction 142(5), 711-721 (2011).
49. Kawai Y, Noguchi J, Akiyama K, et al. A missense mutation of the Dhh gene is associated with male pseudohermaphroditic rats showing impaired leydig cell development. Reproduction 141(2), 217-225 (2011).
50. Bitgood MJ, Shen L, Mcmahon AP. Sertoli cell signaling by desert hedgehog regulates the male germline. Curr. Biol. 6(3), 298-304 (1996).
51. Merchant A, Joseph G, Wang Q, Brennan S, Matsui W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood 115(12), 2391-2396 (2010).
52. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat. Immunol. 2(2), 172-180 (2001).
53. Ehtesham M, Sarangi A, Valadez JG, et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 26(39), 5752-5761 (2007).
54. Thayer SP, Di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425(6960), 851-856 (2003).
55. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933), 1457-1461 (2009).
56. Huang FT, Zhuan-Sun YX, Zhuang YY, et al. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int. J. Oncol. 41(5), 1707-1714 (2012).
57. Sheng T, Li C, Zhang X, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 3, 29 (2004).
58. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431(7009), 707-712 (2004).
59. Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl Acad. Sci. USA 101(34), 12561-12566 (2004).
60. Fan L, Pepicelli CV, Dibble CC, et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145(8), 3961-3970 (2004).
61. Shaw A, Gipp J, Bushman W. The sonic hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts. Oncogene 28(50), 4480-4490 (2009).
62. Levitt RJ, Zhao Y, Blouin MJ, Pollak M. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF II and activation of Akt in PC 3 prostate cancer cells. Cancer Lett. 255(2), 300-306 (2007).
63. Park KS, Martelotto LG, Peifer M, et al. A crucial requirement for hedgehog signaling in small cell lung cancer. Nat. Med. 17(11), 1504-1508 (2011).
64. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422(6929), 313-317 (2003).
65. Tian F, Mysliwietz J, Ellwart J, Gamarra F, Huber RM, Bergner A. Effects of the hedgehog pathway inhibitor GDC 0449 on lung cancer cell lines are mediated by side populations. Clin. Exp. Med. 12(1), 25-30 (2012).
66. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425(6960), 846-851 (2003).
67. Das S, Samant RS, Shevde LA. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis. J. Biol. Chem. 286(11), 9612-9622 (2011).
68. Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 64(17), 6071-6074 (2004).
69. Santini R, Vinci MC, Pandolfi S, et al. Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 30(9), 1808-1818 (2012).
70. Bhattacharya R, Kwon J, Ali B, et al. Role of hedgehog signaling in ovarian cancer. Clin. Cancer Res. 14(23), 7659-7666 (2008).
71. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi 1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66(12), 6063-6071 (2006).
72. Wang X, Venugopal C, Manoranjan B, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 31(2), 187-199 (2012).
73. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25(10), 2524-2533 (2007).
74. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67(5), 2187-2196 (2007).
75. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl Acad. Sci. USA 104(10), 4048-4053 (2007).
76. Wang CY, Wei Q, Han I, et al. Hedgehog and notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res. 72(4), 1013-1022 (2012).
77. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer cell 14(3), 238-249 (2008).
78. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458(7239), 776-779 (2009).
79. Zheang B, Irvine D, Ho YW, et al. Inhibition of chronic myeloid leukemia stem cells by the combination of the hedgehog pathway inhibitor LDE225 with nilotinib. Blood 116(21), 227-227 (2010).
80. Schairer A, Shih A, Geron I, et al. Human blast crisis leukemia stem cell inhibition with a novel smoothened antagonist. Blood 116(21), 523-523 (2010).
81. Okabe S, Tauchi T, Ohyashiki K. GDC 0449, the small molecule inhibitor of hedgehog-Gli pathway for the treatment of bcr-abl positive leukemia cells and in combination with dasatinib. Blood 116(21), 882-883 (2010).
82. Queiroz KCS, Ruela-de-Sousa RR, Fuhler GM, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29(48), 6314-6322 (2010).
83. Kobune M, Takimoto R, Murase K, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 100(5), 948-955 (2009).
84. Pan D, Li Y, Li Z, Wang YZ, Wang PP, Liang Y. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leukemia Res. 36(6), 742-748 (2012).
85. Kobune M, Iyama S, Kikuchi S, et al. Stromal cells expressing hedgehog-interacting protein regulate the proliferation of myeloid neoplasms. Blood Cancer J. 2, e87 (2012).
86. Gao J, Graves S, Koch U, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 4(6), 548-558 (2009).
87. Ji Z, Mei FC, Johnson BH, Thompson EB, Cheng X. Protein kinase A, not EPAC, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J. Biol. Chem. 282(52), 37370-37377 (2007).
88. Lin TL, Wang QH, Brown P, et al. Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI 926. PloS One 5(12), e15262 (2010).
89. Katagiri S, Tauchi T, Okabe S, et al. Targeting the hedgehog signaling pathway in therapy-resistant BCR-ABL1 positive leukemia with ponatinib. Blood 118(21), 30-31 (2011).
90. Tricot GJ, Yang Y, Xu CJ, et al. Targeting myeloma stem cells through simultaneous inhibition of Wnt and hedgehog (Hh) signaling pathways. Blood 116(21), 270-270 (2010).
91. Tricot GJ, Wang SQ, Shi L, et al. Potential eradication of myeloma stem cells by combining ATRA with WNT and HH signaling pathways inhibitors. Blood 114(22), 1109-1109 (2009).
92. Blotta S, Jakubikova J, Calimeri T, et al. Canonical and non canonical hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120(25), 5002-5013 (2012).
93. Blotta S, Negri J, Nanjappa P, et al. Hedgehog pathway as a potential therapeutic target in multiple myeloma. Blood 110(11), 206a-207a (2007).
94. Singh RR, Kunkalla K, Qu C, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B cell lymphoma. Oncogene 30(49), 4874-4886 (2011).
95. Kunkalla K, Qu CJ, Liu YD, Singh R, Vega F. The t(14;18)(q32;q21) confers resistance to apoptosis-induced by smoothened inhibitors in diffuse large B cell lymphoma that can be restored by functional inhibition of Bcl2. Blood 118(21), 1062-1062 (2011).
96. Qu CJ, Liu YD, Kunkalla K, et al. Smoothened (smo), a G protein-coupled receptor (GPCR) activated by hedgehog ligands, modulates the activity levels of PI3K/Akt and NF kB in diffuse large B cell lymphoma. Blood 118(21), 1486-1487 (2011).
97. Chari NS, Teo AEK, Medeiros LJ, Mcdonnell TJ. Simultaneous targeting of SHH/p53 pathways in large B cell lymphomas. Blood 114(22), 689-689 (2009).
98. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B cell malignancies. Nat. Med. 13(8), 944-951 (2007).
99. Hegde GV, Emanuel K, Joshi AD, et al. Sonic hedgehog signaling in mantle cell lymphoma. Blood 108(11), 580a-580a (2006).
100. Hegde GV, Munger CM, Emanuel K, et al. Targeting of sonic hedgehog-gli signaling: a potential strategy to improve therapy for mantle cell lymphoma. Mol. Cancer Ther. 7(6), 1450-1460 (2008).
101. Wang Q, Peacock C, Hensley K, et al. Aberrant hedgehog signaling represents a novel therapeutic target in B cell lymphomas. Blood 110(11), 1048a-1048a (2007).
102. Kim JE, Singh RR, Cho-Vega JH, et al. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B cell lymphoma. Modern Pathol. 22(10), 1312-1320 (2009).
103. Desch P, Asslaber D, Kern D, et al. Inhibition of GLI, but not smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 29(35), 4885-4895 (2010).
104. Decker S, Zirlik K, Djebatchie L, et al. Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for hedgehog-inhibitor responsiveness in CLL. Blood 119(4), 997-1007 (2012).
105. Hartmann D, Schmitt-Graff A, Veelken H, Dierks C. Hedgehog pathway activation via autocrine and paracrine Dhh ligand secretion supports follicular lymphoma growth in vitro. Onkologie 33, 131-131 (2010).
106. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 69(6), 2550-2558 (2009).
107. Walsh KJ, Fan SY, Patel A, et al. Hedgehog pathway inhibition is a novel therapeutic approach in lymphomas and its efficacy is inversely related to PI3 kinase inhibition. Blood 116(21), 770-770 (2010).
108. Alayed K, Kunkalla K, Qu C, et al. Glioma-associated oncogene homologue 3, a hedgehog transcription factor, contributes to the classical Hodgkin lymphoma microenvironment through the modulation of a subset of inflammatory chemokines and cytokines. Modern Pathol. 25, 321a-321a (2012).
109. Greaves WO, Kim JE, Singh RR, et al. Glioma-associated oncogene homologue 3, a hedgehog transcription factor, is highly expressed in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hum. Pathol. 42(11), 1643-1652 (2011).
110. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280(5369), 1603-1607 (1998).
111. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 16(21), 2743-2748 (2002).
112. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 406(6799), 1005-1009 (2000).
113. Lorusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC 0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17(8), 2502-2511 (2011).
114. Von Hoff DD, Lorusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361(12), 1164-1172 (2009).
115. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366(23), 2171-2179 (2012).
116. Metcalfe C, De Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against smoothened antagonists. Cancer Res. 71(15), 5057-5061 (2011).
117. Jamieson C, Cortes JE, Oehler V, et al. Phase 1 dose-escalation study of PF 04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. Blood 118(21), 195-196 (2011).
118. Huff CA, Padmanabhan S, Kelly KR, et al. A Phase I study of an oral hedgehog pathway antagonist, BMS 833923, in patients with relapsed or refractory multiple myeloma. Blood 118(21), 1709-1709 (2011).
119. Siu LL, Papadopoulos K, Alberts SR. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J. Clin. Oncol. 28(Suppl. 15), abstract 2501 (2010).
120. Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI 926) increases lifespan in a mouse medulloblastoma model. Proc. Natl Acad. Sci. USA 109(20), 7859-7864 (2012).
121. Geoerger B, Aerts I, Casanova M, et al. Updated results from a Phase I study of LDE225, a smoothened antagonist, in pediatric patients with recurrent medulloblastoma or other solid tumors. Pediatr. Blood Cancer 59(6), 980-980 (2012).
122. Goldman JW, Eckhardt SG, Borad M, et al. Phase 1 dose-escalation trial of the investigational hedgehog (Hh) pathway inhibitor TAK 441 in patients with advanced solid tumors. Ann. Oncol. 23, 156-156 (2012).
123. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer cell 17(4), 388-399 (2010).
124. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells. Cancer cell 22(3), 373-388 (2012).
125. Grachtchouk M, Mo R, Yu S, et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 24(3), 216-217 (2000).
126. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl Acad. Sci. USA 104(20), 8455-8460 (2007).
127. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog/Gli pathway. J. Clin. Invest. 121(1), 148-160 (2011).
128. Ericson J, Morton S, Kawakami A, Roelink H, Jessell TM. Two critical periods of sonic hedgehog signaling required for the specification of motor neuron identity. Cell 87(4), 661-673 (1996).
129. Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 5(3), 154-156 (2009).
130. Yan H, Wang YC, Li D, et al. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase cdelta. Leukemia 21(7), 1488-1495 (2007).
131. Cai YX, Meng FY, Sun QX, Fu YB, Li L. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 29(11), 737-740 (2008).
132. Canestraro M, Galimberti S, Savli H, et al. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet. Cytogenet. 199(2), 110-120 (2010).
133. Altman JK, Yoon P, Katsoulidis E, et al. Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. J. Biol. Chem. 283(4), 1992-2001 (2008).
134. Yoon P, Giafis N, Smith J, et al. Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. Mol. Cancer Ther. 5(11), 2815-2823 (2006).
135. Sharma M, Khan H, Thall PF, et al. A randomized Phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9), 2507-2515 (2012).
136. De Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116(23), 5420-5431 (2010).
137. Guha M. Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential. Nat. Rev. Drug Discov. 11(4), 257-258 (2012).
138. Catenacci DVT, Bahary N, Edelman MJ, et al. A Phase IB/randomized Phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): interim analysis of a University of Chicago Phase II consortium study. J. Clin. Oncol. 30(Suppl.), abstract 4022 (2012).
139. Palmer SR, Erlichman C, Fernandez-Zapico M, et al. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J. Clin. Oncol. 29(Suppl.), abstract 3092 (2011).
140. Gounder MM, Dickson MA, Wu N, et al. A first-in-human, Phase IB combination study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a hedgehog inhibitor, GDC-0449, with a Notch inhibitor, RO4929097, in patients with advanced sarcoma. J. Clin. Oncol. 30(Suppl.), abstract 10004 (2012).
141. Italiano A, Le Cesne A, Cassier PA, et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes Phase II collaborative study. J. Clin. Oncol. 30(Suppl.), abstract 10005 (2012).
142. Gajjar AJ, Stewart CF, Ellison DW, et al. A Phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium study (PBTC 25). J. Clin. Oncol. 28(Suppl. 18), abstract CRA9501 (2010).
143. Berlin J, Bendell J, Hart LL, et al. A Phase 2, randomized, double-blind, placebo controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (MCRC). Ann. Oncol. 21(Suppl. 8), viii1-viii12 (2010).
144. Rudin CM, Jimeno A, Miller WH, et al. A Phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J. Clin. Oncol. 29(Suppl.), abstract 3014 (2011).
145. Ko AH, LoConte NK, Kantoff E, et al. A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). J. Clin. Oncol. 30(Suppl.), abstract 3105 (2012).
146. Richards DA, Stephenson J, Wolpin BM, et al. A Phase IB trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. J. Clin. Oncol. 30(Suppl. 4), abstract 213 (2012).
147. Geoerger B, Aerts I, Casanova M, et al. A Phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. J. Clin. Oncol. 30(Suppl.), abstract 9519 (2012).
148. Ahnert JR, Baselga J, Tawbi HA, et al. A Phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J. Clin. Oncol. 28(Suppl. 15), abstract 2500 (2010).
149. ClinicalTrials.gov. Phase 2 dasatinib combo with smoothened (SMO) antagonist (BMS 833923). http://clinicaltrial.gov/ct2/show/NCT01357655?term= NCT01357655&rank=1
150. ClinicalTrials.gov. Dasatinib combo with SMO inhibitor (BMS 833923). http://clinicaltrial.gov/ct2/show/NCT01218477?term=NCT01218477 &rank=1
151. ClinicalTrials.gov. A study of BMS 833923 with cisplatin and capecitabine in inoperable, metastatic gastric, gastroesophageal, or esophageal adenocarcinomas. http://clinicaltrial.gov/ct2/show/NCT00909402?term=NCT00909402 &rank=1
152. ClinicalTrials.gov. A study of BMS 833923 with carboplatin and etoposide followed by BMS 833923 alone in subjects with extensive stage small cell lung cancer. http://clinicaltrial.gov/ct2/show/NCT00927875?term=NCT00927875 &rank=1
153. ClinicalTrials.gov. Multiple ascending dose (MAD) combination in subjects with multiple myeloma. http://clinicaltrial.gov/ct2/show/NCT00884546?term= NCT00884546 &rank=1
154. ClinicalTrials.gov. Phase 1 multiple ascending dose study of BMS 833923 (XL139) in subjects with solid tumors. http://clinicaltrial.gov/ct2/show/ NCT01413906?term=NCT01413906 &rank=1
155. ClinicalTrials.gov. A Phase 1 study of BMS 833923 (XL139) in subjects with advanced or metastatic cancer. http://clinicaltrial.gov/ct2/show/ NCT00670189?term=NCT00670189 &rank=1
156. ClinicalTrials.gov. Pilot study of cetuximab and the hedgehog inhibitor IPI 926 in recurrent head and neck cancer. http://clinicaltrial.gov/ct2/show/ NCT01255800?term=NCT01255800 &rank=1
157. ClinicalTrials.gov. FOLFIRINOX plus IPI 926 for advanced pancreatic adenocarcinoma (2013). http://clinicaltrial.gov/ct2/show/NCT01383538?term= NCT01383538 &rank=1
158. ClinicalTrials.gov. IPI 926 extension protocol for continuation of treatment with IPI 926. http://clinicaltrial.gov/ct2/show/NCT01609179?term= NCT01609179 &rank=1
159. ClinicalTrials.gov. A safety and efficacy study of patients with metastatic or locally advanced (unresectable) chondrosarcoma. http://clinicaltrial.gov/ct2/show/NCT01310816?term=NCT01310816 &rank=1
160. ClinicalTrials.gov. Nilotinib and LDE225 in the treatment of chronic or accelerated phase myeloid leukemia in patients who developed resistance to prior therapy. http://clinicaltrial.gov/ct2/show/NCT01456676?term=NCT01456676 &rank=1
161. ClinicalTrials.gov. A study of LY2940680 in small cell lung cancer. http://clinicaltrial.gov/ct2/show/NCT01722292?term=NCT01722292 &rank=1
162. ClinicalTrials.gov. A dose finding and safety study of oral LEQ506 in patients with advanced solid tumors. http://clinicaltrial.gov/ct2/show/ NCT01106508?term=NCT01106508 &rank=1